Related Experiment Videos
Novel mechanisms of antiprogestin action
K B Horwitz1, L Tung, G S Takimoto
1University of Colorado Health Sciences Center, Department of Medicine, Denver 80262, USA.
Abstract:
Endocrine therapy used either prophylactically or therapeutically for the treatment of locally advanced or metastatic breast cancers offers many advantages to patients whose tumors contain functional estrogen (ER) and progesterone (PR) receptors. The range of treatments defined as endocrine include surgical ablation of endocrine glands, administration of pharmacologic doses of steroid hormones, chemical blockade of steroid hormone biosynthesis, and inhibition of endogenous steroid hormone action at the tumor with synthetic antagonists. The last of these approaches is the most widely used, making the antiestrogen tamoxifen the preferred first-line therapeutic agent for treatment of hormone-dependent metastatic breast cancer. The wide-spread use of tamoxifen reflects its efficacy and low toxicity, and the fact that it makes good physiological sense to block the local proliferative effects of estrogens directly at the breast. But are estrogens the only hormones with a proliferative impact on the breast and on breast cancers? This chapter focuses on evidence that progesterone also has proliferative actions in the breast; on preliminary data showing that progesterone antagonists may be new tools for the management of metastatic breast cancer; and on recent data suggesting that antiprogestin-occupied PR have novel mechanisms of action that bear on tissue specificity and development of hormone resistance.
Insights
Progesterone, like estrogen, can promote breast cancer growth. Progesterone antagonists show promise as a new therapeutic strategy for metastatic breast cancer, potentially overcoming hormone resistance.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Endocrine therapy is crucial for hormone receptor-positive breast cancers.
- Tamoxifen, an antiestrogen, is a widely used first-line treatment for metastatic breast cancer.
- The role of progesterone in breast cancer proliferation is increasingly recognized.
Purpose of the Study:
- To explore the proliferative effects of progesterone in breast cancer.
- To investigate the potential of progesterone antagonists as a novel therapeutic approach.
- To examine the mechanisms of action of antiprogestin-occupied progesterone receptors (PR).
Main Methods:
- Review of existing literature on hormone therapy in breast cancer.
- Analysis of preclinical and clinical data on progesterone's role.
- Examination of studies on progesterone antagonists and their mechanisms.
Main Results:
- Evidence suggests progesterone possesses proliferative actions in breast tissue and cancers.
- Preliminary data indicate progesterone antagonists may offer new treatment options.
- Antiprogestin-occupied PR exhibit novel mechanisms influencing tissue specificity and hormone resistance.
Conclusions:
- Progesterone's proliferative role in breast cancer warrants further investigation.
- Progesterone antagonists represent a promising avenue for managing metastatic breast cancer.
- Understanding antiprogestin-occupied PR mechanisms may lead to improved therapeutic strategies and overcome resistance.